Clinical Trial

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 15, 2026 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-03-15 -> 2026-06-15 2026-05-16
Trial Details
NCT Number NCT04969835
Lead Sponsor Avacta Life Sciences Ltd
Conditions Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer, Soft Tissue Sarcoma
Enrollment 158 participants
Start Date 2021-07-16
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-15